what a sad, pitiful existence it is to think that you have less than 5 years left to contribute intellectually to the world

Aging is what happens when the immune system systematically retreats from tissue repair, regeneration and maintenance in order to protect major organs from immediate death. Short term survival at the cost of aged bone marrow/systemic aging.

We built this in 100 days. But there are still so many statues to build. Alexander the Great, Caesar, Augustus. Galileo, Newton. Napoleon, Washington, Benjamin Franklin. The great men of the past will come back to haunt us and push us toward greatness.

AT&T, Verizon, and T-Mobile are jointly lobbying the FCC to preserve existing rules as @SpaceX moves closer to launching its own independent cellular network that would compete directly with the three major U.S. carriers. On Oct 20th, reps from all three major U.S. wireless carriers met with FCC officials to push back against proposed changes that would give satellite companies more freedom to offer cellular service. The carriers urged the FCC to: • Block satellite companies from using certain 5G frequencies currently used by wireless carriers. • Keep rules requiring satellite companies to get permission from wireless carriers before using their licensed spectrum. • Allow wireless carriers to maintain control over these agreements, including the ability to end them. • Reconsider proposed interference limits to protect existing cellular networks. Based on all the public communications from these carriers, and the lobbying, they are clearly worried that SpaceX's @Starlink Mobile network is going to be a major competitor to them. Starlink Mobile will become the first network operator to deploy both satellite and terrestrial spectrum. The FCC recently announced that they are considering new rules that could make it easier for satellite companies like SpaceX to offer cellular service without relying as heavily on existing wireless carriers, so this is partly what the three big carriers are fighting against.

> T cells trigger severe gut lining damage > GLP agonists directly protect against intestinal destruction > I'm going to test this on myself

Chemistry really is the final frontier. Or rather the first place where computationalists realize the universe is indeed not a computer.

How To: Genetically Modify a Flower 🧬🌹

Biotech still runs on who owns the patent and who approves the drug. That was my takeaway from @alexkesin's session at DataDrivenPharma West last week. Alex wrote one of the most widely shared analyses of China's biotech rise this year, and it has become a reference point in the policy debate. He also co-hosts @approvedfm with [@MatthewPech], a podcast on how drugs get discovered, developed and sold. He walked a room of operators through where the value sits now. Four quick hits: - 1:3. Doing the work in China costs a half to a third of the US price. - Rent, don't sell. Beijing's new export controls block the sale of biotech platforms. Licensing, partnerships and contract research stay open. - 3x. China tripled its university patent conversion rate in two years, to 10.1%. - 8% to 32%. China's share of the global early-stage pipeline, from 2015 to 2024. The first hit explains the last five years. China got cheap and fast, and the West bought what it built. Most of those deals were fast-follows on targets Western labs discovered. The West owned the original IP and rented China's speed. The other three point to the next five. The export controls dropped the same morning as the session. Read them next to the new five-year plan, which makes biotech and biomanufacturing a national priority through 2030. The strategy looks clear to me. Generate IP faster than the US, keep ownership at home, and let the world license it. Pipeline share has quadrupled. Patents are moving out of universities and into companies. Nine out of ten still sit unused, so there's plenty of room to grow. Patents are still the currency. Regulators still set the exchange rate. The FDA turned away a Chinese PD-1 copycat because its trial ran only on Chinese patients. To get paid in the US, you still need FDA approval and a partner who can launch here. What changes is who holds the paper. When the West generated the IP, licensing meant Western companies owned the value and paid for speed. As more IP is generated and kept in China, the same deal structure sends more value the other way. The West ends up renting the molecule instead of owning it. This is a gold rush for intellectual property. The question is who can generate novel IP in a specific area, and do it first. Therapeutics is the beachhead. The US market pays enough for new drugs that the long road through the FDA still earns a return. In this gold rush, anyone can be a miner. The fastest ones will have the best maps. And maps only come from data. #ddpwest26

Big shoutout to all of our partners for making Nemotron 3.5 Super VL their own through post-training 🙌 Here’s what they’ve built 🧵

Most children (and adults) can identify 100+ logos and nearly 0 native plant species This is not healthy for society Native wildlife roots us in our place and we should treat it with such reverence If we do not root ourselves in the land it is very easy to lose our ourselves

Over the past month, we completely switched to frontier LLMs to control a robot in a customer deployment. By doing this, we have a classic System 1/System 2 architecture, but on steroids. For the high-level reasoning layer, we use an agent based on Opus and Astra, which are many generations more capable than any VLA. For the fast execution layer, we use computer vision code written by the model, which is fast, editable, and reliable. As a bonus, we got in-context learning, which is just a basic feature of LLMs, and continual learning, since whenever a new situation arises, the large model steps in and adapts the pipeline. And it just feels better to be on the right side of the Bitter Lesson, benefiting from the billions being invested in frontier models around the world.

I'm so excited to be releasing this engine. This represents the first of hopefully a long line of work with Nvidia We didn't put comparison charts in the main post but rest assured WE SMOKED EM this is the best engine for your dgx station. its not close.